Sleep, sleep-disordered breathing and metabolic consequences

European Respiratory Journal

Volumn 34, Issue 1, 2009, Pages 243-260

  Levy P ^a,e   Bonsignore, M R ^b,c   Eckel, J ^d  

^a INSERM   (France)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR Consiglio Nazionale delle Ricerche   (Italy)

^d LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetes; Insulin resistance; Intermittent hypoxia; Obesity; Sleep; Sleep apnoea

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HUMAN; HYPOXIA; INFLAMMATION; INSULIN RESISTANCE; INSULINEMIA; METABOLIC SYNDROME X; METABOLISM; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PATHOGENESIS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; REVIEW; SLEEP; SLEEP APNEA SYNDROME; WORLD HEALTH ORGANIZATION;

ADIPOSE TISSUE; ADULT; AGED; ANIMALS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY; SLEEP; SLEEP APNEA SYNDROMES;

EID: 69249096169     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00166808     Document Type: Review

References (194)

1. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
2. Arzt M, Young T, Finn L, et al. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005; 172: 1447-1451.
3. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342: 1378-1384.
4. Doherty LS, Kiely JL, Swan V, et al. Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. Chest 2005; 127: 2076-2084.
5. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-1078.
6. Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31: 1079-1085.
7. Gami AS, Somers VK. Obstructive sleep apnoea, metabolic syndrome, and cardiovascular outcomes. Eur Heart J 2004; 25: 709-711.
8. McNicholas WT, Bonsignore MR. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156-178.
9. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008; 5: 207-217.
10. Coughlin SR, Mawdsley L, Mugarza JA, et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-741.
11. Bonsignore MR, Zito A. Metabolic effects of the obstructive sleep apnea syndrome and cardiovascular risk. Arch Physiol Biochem 2008; 114: 255-260.
12. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778.
13. Sundström J, Risérus U, Byberg L, et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878-882.
14. Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest 2008; 133: 496-506.
15. Shaw JE, Punjabi NM, Wilding JP, et al. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 2008; 81: 2-12.
16. Punjabi NM, Shahar E, Redline S, et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol 2004; 160: 521-530.
17. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 2006; 61: 945-950.
18. Knutson KL, Spiegel K, Penev P, et al. The metabolic consequences of sleep deprivation. Sleep Med Rev 2007; 11: 163-178.
19. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999; 354: 1435-1439.
20. Spiegel K, Tasali E, Penev P, et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med 2004; 141: 846-850.
21. Tasali E, Leproult R, Ehrmann DA, et al. Slow-wave sleep and the risk of type 2 diabetes in humans. Proc Natl Acad Sci USA 2008; 105: 1044-1049.
22. Taheri S, Lin L, Austin D, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med 2004; 1: e62.
23. Chaput JP, Despres JP, Bouchard C, et al. Short sleep duration is associated with reduced leptin levels and increased adiposity: results from the Quebec family study. Obesity 2007; 15: 253-261.
24. Hasler G, Buysse DJ, Klaghofer R, et al. The association between short sleep duration and obesity in young adults: a 13-year prospective study. Sleep 2004; 27: 661-666.
25. Nilsson PM, Roost M, Engstrom G, et al. Incidence of diabetes in middle-aged men is related to sleep disturbances. Diabetes Care 2004; 27: 2464-2469.
26. Mallon L, Broman J-E, Hetta J. High incidence of diabetes in men with sleep complaints or short sleep duration: a 12-year follow-up study of a middle-aged population. Diabetes Care 2005; 28: 2762-2767.
27. Marshall NS, Glozier N, Grunstein RR. Is sleep duration related to obesity? A critical review of the epidemiological evidence. Sleep Med Rev 2008; 12: 289-298.
28. Taheri S, Thomas GN. Is sleep duration associated with obesity-where do U stand? Sleep Med Rev 2008; 12: 299-302.
29. Marshall NS, Glozier N, Grunstein RR. Is sleep duration associated with obesity-U cannot be serious. Sleep Med Rev 2008; 12: 303-305.
30. Bliwise DL, Young TB. The parable of parabola: what the U-shaped curve can and cannot tell us about sleep. Sleep 2007; 30: 1614-1615.
31. Patel SR, Hu FB. Short sleep duration and weight gain: a systematic review. Obesity 2008; 16: 643-653.
32. Cappuccio FP, Taggart FM, Kandala NB, et al. Meta-analysis of short sleep duration and obesity in children and adults. Sleep 2008; 31: 619-626.
33. Stranges S, Cappuccio FP, Kandala NB, et al. Cross-sectional versus prospective associations of sleep duration with changes in relative weight and body fat distribution: the Whitehall II Study. Am J Epidemiol 2008; 167: 321-329.
34. Horne J. Short sleep is a questionable risk factor for obesity and related disorders: statistical versus clinical significance. Biol Psychol 2008; 77: 266-276.
35. Horne J. Too weighty a link between short sleep and obesity? Sleep 2008; 31: 595-596.
36. Young T. Increasing sleep duration for a healthier (and less obese?) population tomorrow. Sleep 2008; 31: 593-594.
37. Vgontzas AN, Zoumakis E, Bixler EO, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004; 89: 2119-2126.
38. Haack M, Sanchez E, Mullington JM. Elevated inflammatory markers in response to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. Sleep 2007; 30: 1145-1152.
39. Irwin MR, Wang M, Campomayor CO, et al. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006; 166: 1756-1762.
40. Irwin MR, Wang M, Ribeiro D, et al. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry 2008; 64: 538-540.
41. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003; 100: 1920-1925.
42. Irwin M, Thompson J, Miller C, et al. Effects of sleep and sleep deprivation on catecholamine and interleukin-2 levels in humans: clinical implications. J Clin Endocrinol Metab 1999; 84: 1979-1985.
43. Irwin MR, Ziegler M. Sleep deprivation potentiates activation of cardiovascular and catecholamine responses in abstinent alcoholics. Hypertension 2005; 45: 252-257.
44. Knutson KL, Van Cauter E. Associations between sleep loss and increased risk of obesity and diabetes. Ann NY Acad Sci 2008; 1129: 287-304.
45. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Ann Rev Neurosci 2002; 25: 283-313.
46. Sakurai T. Roles of orexin/hypocretin in regulation of sleep/ wakefulness and energy homeostasis. Sleep Med Rev 2005; 9: 231-241.
47. Spiegel K, Knutson K, Leproult R, et al. Sleep loss: a novel risk factor for insulin resistance and type 2 diabetes. J Appl Physiol 2005; 99: 2008-2019.
48. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: Suppl. 1, S55-S60.
49. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
50. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Geneva, World Health Organization, 1999.
51. Grunstein RR, Stenlöf K, Hedner J, et al. Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int J Obes Relat Metab Disord 1995; 19: 410-418.
52. Elmasry A, Janson C, Lindberg E, et al. The role of habitual snoring and obesity in the development of diabetes: a 10-year follow-up study in a male population. J Intern Med 2000; 248: 13-20.
53. Elmasry A, Lindberg E, Berne C, et al. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med 2001; 249: 153-161.
54. Punjabi NM, Sorkin JD, Katzel LI, et al. Sleep disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 2002; 165: 677-682.
55. Al-Delaimy WK, Manson JE, Willett WC, et al. Snoring as a risk factor for type II diabetes mellitus: a prospective study. Am J Epidemiol 2002; 155: 387-393.
56. Reichmuth KJ, Austin D, Skatrud JB, et al. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005; 172: 1590-1595.
57. Shin C, Kim J, Kim J, et al. Association of habitual snoring with glucose and insulin metabolism in nonobese Korean adult men. Am J Respir Crit Care Med 2005; 171: 287-291.
58. Lam JCM, Lam B, Lam C-L, et al. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese adults in Hong Kong. Respir Med 2006; 100: 980-987.
59. Joo SL, Choi HA, Kim J, et al. Habitual snoring is associated with elevated hemoglobin A1c levels in non-obese middle-aged adults. J Sleep Res 2006; 15: 437-444.
60. Onat A, Hergenç G, Uyarel H, et al. Obstructive sleep apnea syndrome is associated with metabolic syndrome rather than insulin resistance. Sleep Breath 2007; 11: 23-30.
61. Seicean S, Kirchner HL, Gottlieb DJ, et al. Sleep-disordered breathing and impaired glucose metabolism in normal-weight and overweight/obese individuals. Diabetes Care 2008; 31: 1001-1006.
62. Theorell-Haglow J, Berne C, Janson C, et al. Obstructive sleep apnoea is associated with decreased insulin sensitivity in females. Eur Respir J 2008; 31: 1054-1060.
63. Bjorkelund C, Bondyr-Carlsson D, Lapidus L, et al. Sleep disturbances in midlife unrelated to 32-year diabetes incidence: the prospective population study of women in Gothenburg. Diabetes Care 2005; 28: 2739-2744.
64. Stoohs RA, Facchini F, Guilleminault C. Insulin resistance and sleep-disordered breathing in healthy humans. Am J Respir Crit Care Med 1996; 154: 170-174.
65. Gruber A, Horwood F, Sithole J, et al. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. Cardiovasc Diabetol 2006; 5: 22.
66. Katsumata K, Okada T, Miyao M, et al. High incidence of sleep apnea syndrome in a male diabetic population. Diabetes Res Clin Pract 1991; 13: 45-51.
67. Tiihonen M, Partinen M, Närvänen S. The severity of obstructive sleep apnoea is associated with insulin resistance. J Sleep Res 1993; 2: 56-61.
68. Strohl KP, Novak RD, Singer W, et al. Insulin levels, blood pressure and sleep apnea. Sleep 1994; 17: 614-618.
69. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-1158.
70. Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165: 670-676.
71. Meslier N, Gagnadoux F, Giraud P, et al. Impaired glucoseinsulin metabolism in males with obstructive sleep apnoea syndrome. Eur Respir J 2003; 22: 156-160.
72. Tassone F, Lanfranco F, Gianotti L, et al. Obstructive sleep apnoea syndrome impairs insulin sensitivity independently of anthropometric variables. Clin Endocrinol (Oxf) 2003; 59: 374-379.
73. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol 2006; 64: 12-19.
74. Peled N, Kassirer M, Shitrit D, et al. The association of OSA with insulin resistance, inflammation and metabolic syndrome. Respir Med 2007; 101: 1696-1701.
75. McArdle N, Hillman D, Beilin L, et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 2007; 175: 190-195.
76. Kapsimalis F, Varouchakis G, Manousaki A, et al. Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. Lung 2008; 186: 209-217.
77. Barcelo A, Barbe F, de la Pena M, et al. Insulin resistance and daytime sleepiness in patients with sleep apnea. Thorax 2008; 63: 946-950.
78. Davies RJ, Turner R, Crosby J, et al. Plasma insulin and lipid levels in untreated obstructive sleep apnoea and snoring; their comparison with matched controls and response to treatment. J Sleep Res 1994; 3: 180-185.
79. Barceló A, Barbé F, Llompart E, et al. Effects of obesity on C-reactive protein level and metabolic disturbances in male patients with obstructive sleep apnea. Am J Med 2004; 117: 118-121.
80. Sharma SK, Kumpawat S, Goel A, et al. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007; 8: 12-17.
81. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical reappraisal. Diabetes Care 2005; 28: 2289-2304.
82. Kahn R. Metabolic syndrome: is it a syndrome? Does it matter? Circulation 2007; 115: 1806-1810.
83. Beaser RS, Levy P. Metabolic syndrome: a work in progress, but a useful construct. Circulation 2007; 115: 1812-1818.
84. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006; 444: 881-887.
85. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005; 366: 1059-1062.
86. Opie LH. Metabolic syndrome. Circulation 2007; 115: e32-e35.
87. Despres J-P, Lemieux I, Bergeron J, et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008; 28: 1039-1049.
88. Sasanabe R, Banno K, Otake K, et al. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens Res 2006; 29: 315-322.
89. Shiina K, Tomiyama H, Takata Y, et al. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk: a sleep clinic cohort study. Hypertens Res 2006; 29: 433-441.
90. Kono M, Tatsumi K, Saibara T, et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387-1392.
91. Tkacova R, Dorkova Z, Molcanyiova A, et al. Cardiovascular risk and insulin resistance in patients with obstructive sleep apnea. Med Sci Monit 2008; 14: CR438-CR444.
92. Punjabi NM, Ahmed MM, Polotsky VY, et al. Sleep-disordered breathing, glucose intolerance, and insulin resistance. Respir Physiol Neurobiol 2003; 136: 167-178.
93. Vgontzas AN, Zoumakis E, Bixler EO, et al. Selective effects of CPAP on sleep apnoea-associated manifestations. Eur J Clin Invest 2008; 38: 585-595.
94. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a manifestation of the metabolic syndrome. Sleep Med Rev 2005; 9: 211-224.
95. Saini J, Krieger J, Brandenberger G, et al. Continuous positive airway pressure treatment. Effects on growth hormone, insulin and glucose profiles in obstructive sleep apnea patients. Horm Metab Res 1993; 25: 375-381.
96. Brooks B, Cistulli PA, Borkman M, et al. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsiveness. J Clin Endocrinol Metab 1994; 79: 1681-1685.
97. Cooper BG, White JE, Ashworth LA, et al. Hormonal and metabolic profiles in subjects with obstructive sleep apnea syndrome and the acute effects of nasal continuous positive airway pressure (CPAP) treatment. Sleep 1995; 18: 172-179.
98. Saarelainen S, Lahtela J, Kallonen E. Effect of nasal CPAP treatment on insulin sensitivity and plasma leptin. J Sleep Res 1997; 6: 146-147.
99. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169: 156-162.
100. Hassaballa HA, Tulaimat A, Herdegen JJ, et al. The effect of continuous positive airway pressure on glucose control in diabetic patients with severe obstructive sleep apnea. Sleep Breath 2005; 9: 176-180.
101. Czupryniak L, Loba J, Pawlowski M, et al. Treatment with continuous positive airway pressure may affect blood glucose levels in nondiabetic patients with obstructive sleep apnea syndrome. Sleep 2005; 28: 601-603.
102. Babu AR, Herdegen J, Fogelfeld L, et al. Type 2 diabetes, glycemic control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005; 165: 447-452.
103. Trenell MI, Ward JA, Yee BJ, et al. Influence of constant positive airway pressure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. Diabetes Obes Metab 2007; 9: 679-687.
104. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29: 720-727.
105. West SD, Nicoll DJ, Wallace TM, et al. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-974.
106. Dorkova Z, Petrasova D, Molcanyiova A, et al. Effects of CPAP on cardiovascular risk profile in patients with severe obstructive sleep apnea and metabolic syndrome. Chest 2008; 134: 686-692.
107. Pallayova M, Donic V, Tomori Z. Beneficial effects of severe sleep apnea therapy on nocturnal glucose control in persons with type 2 diabetes mellitus. Diab Res Clin Pract 2008; 81: e8-e11.
108. Schahin SP, Nechanitzki T, Dittel C, et al. Long-term improvement of insulin sensitivity during CPAP therapy in the obstructive sleep apnoea syndrome. Med Sci Monit 2008; 14: CR117-CR121.
109. Dawson A, Abel SL, Loving RT, et al. CPAP therapy of obstructive sleep apnea in type 2 diabetics improves glycemic control during sleep. J Clin Sleep Med 2008; 4: 538-542.
110. Grunstein RR, Stenlöf KS, Hedner JA, et al. Two year reduction in sleep apnea symptoms and associated diabetes incidence after weight loss in severe obesity. Sleep 2007; 30: 703-710.
111. Chin K, Shimizu K, Nakamura T, et al. Changes in intraabdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999; 100: 706-712.
112. Harsch IA, Schahin SP, Bruckner K, et al. The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes. Respiration 2004; 71: 252-259.
113. Harsch IA, Hahn EG, Pour Schahin S. Effect of CPAP on insulin resistance in patients with obstructive sleep apnoea and type 2 diabetes. Thorax 2008; 63: 384-385.
114. McNicholas WT. Cardiovascular outcomes of CPAP therapy in obstructive sleep apnea syndrome. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1666-R1670.
115. Börgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 2006; 27: 121-127.
116. Steiropoulos P, Tsara V, Nena E, et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. Chest 2007; 132: 843-851.
117. Lindberg E, Berne C, Elmasry A, et al. CPAP treatment of a population-based sample-what are the benefits and the treatment compliance? Sleep Med 2006; 7: 553-560.
118. Sandhu MS, Heald AH, Gibson JM, et al. Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study. Lancet 2002; 359: 1740-1745.
119. Juul A, Scheike T, Davidsen M, et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002; 106: 939-944.
120. Aguilera CM, Gil-Campos M, Canete R, et al. Alterations in plasma and tissue lipids associated with obesity and metabolic syndrome. Clin Sci 2008; 114: 183-193.
121. Nagakawa Y, kishida K, Kihara S, et al. Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea-hypopnea syndrome. Am J Physiol 2008; 294: E778-E784.
122. Zhang XL, Yin KS, Li C, et al. Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J 2007; 120: 1477-1481.
123. Masserini B, Morpurgo PS, Donadio F, et al. Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 2006; 29: 700-705.
124. Kohler M, Ayers L, Pepperell JC, et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 2009; 64: 67-73.
125. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
126. Lobstein T, Jackson-Leach R. Child overweight and obesity in the USA: prevalence rates according to IOTF definitions. Int J Pediatric Obes 2007; 2: 62-64.
127. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
128. Goodman E, Daniels SR, Meigs JB, et al. Instability in the diagnosis of metabolic syndrome in adolescents. Circulation 2007; 115: 2316-2322.
129. Dayyat E, Kheirandish-Gozal L, Gozal D. Childhood obstructive sleep apnea: one or two distinct entities? Sleep Med Clin 2007; 2: 433-444.
130. Verhulst SL, Rooman R, Van Gaal L, et al. Is sleep-disordered breathing an additional risk factor for the metabolic syndrome in obese children and adolescents? Int J Obes 2009; 33: 8-13.
131. Redline S, Storfer-Isser A, Rosen CL, et al. Association between metabolic syndrome and sleep-disordered breathing in adolescents. Am J Respir Crit Care Med 2007; 176: 401-408.
132. de la Eva RC, Baur LA, Donaghue KC, et al. Metabolic correlates with obstructive sleep apnea in obese subjects. J Pediatr 2002; 140: 654-659.
133. Li AM, Chan MH, Chan DF, et al. Insulin and obstructive sleep apnea in obese Chinese children. Pediatr Pulmonol 2006; 41: 1175-1181.
134. Tauman R, O'Brien LM, Ivanenko A, et al. Obesity rather than severity of sleep-disordered breathing as the major determinant of insulin resistance and altered lipidemia in snoring children. Pediatrics 2005; 116: e66-e73.
135. Waters KA, Sitha S, O'Brien LM, et al. Follow-up on metabolic markers in children treated for obstructive sleep apnea. Am J Respir Crit Care Med 2006; 174: 455-460.
136. Kaditis AG, Alexopoulos EI, Damani E, et al. Obstructive sleep-disordered breathing and fasting insulin levels in nonobese children. Pediatr Pulmonol 2005; 40: 515-523.
137. Tauman R, Serpero LD, Capdevila OS, et al. Adipokines in children with sleep disordered breathing. Sleep 2007; 30: 443-449.
138. Gozal D, Capdevila OS, Kheirandish-Gozal L. Metabolic alterations and systemic inflammation in obstructive sleep apnea among nonobese and obese prepubertal children. Am J Respir Crit Care Med 2008; 177: 1142-1149.
139. Nakra N, Bhargava S, Dzuira J, et al. Sleep-disordered breathing in children with metabolic syndrome: the role of leptin and sympathetic nervous system activity and the effect of continuous positive airway pressure. Pediatrics. 2008; 122: e634-e642.
140. Apostolidou MT, Alexopoulos EI, Damani E, et al. Absence of blood pressure, metabolic, and inflammatory marker changes after adenotonsillectomy for sleep apnea in Greek children. Pediatr Pulmonol 2008; 43: 550-560.
141. Verhulst SL, Van Gaal L, De Backer W, et al. The prevalence, anatomical correlates and treatment of sleep-disordered breathing in obese children and adolescents. Sleep Med Rev 2008; 12: 339-346.
142. Kohler MJ, van den Heuvel CJ. Is there a clear link between overweight/obesity and sleep disordered breathing in children? Sleep Med Rev. 2008; 12: 347-361.
143. Spruyt K, Gozal D. Mr. Pickwick and his child went on a field trip and returned almost empty handed...What we do not know and imperatively need to learn about obesity and breathing during sleep in children!. Sleep Med Rev 2008; 12: 335-338.
144. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
145. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60: 329-339.
146. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
147. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
148. Ip MS, Lam KS, Ho C, et al. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-586.
149. Ozturk L, Unal M, Tamer L, et al. The association of the severity of obstructive sleep apnea with plasma leptin levels. Arch Otolaryngol Head Neck Surg 2003; 129: 538-540.
150. Phillips BG, Kato M, Narkiewicz K, et al. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am J Physiol Heart Circ Physiol 2000; 279: H234-H237.
151. Ulukavak Ciftci T, Kokturk O, Bukan N, et al. Leptin and ghrelin levels in patients with obstructive sleep apnea syndrome. Respiration 2005; 72: 395-401.
152. Kapsimalis F, Varouchakis G, Manousaki A, et al. Association of sleep apnea severity and obesity with insulin resistance, C-reactive protein, and leptin levels in male patients with obstructive sleep apnea. Lung 2008; 186: 209-217.
153. Sanner BM, Kollhosser P, Buechner N, et al. Influence of treatment on leptin levels in patients with obstructive sleep apnoea. Eur Respir J 2004; 23: 601-604.
154. Harsch IA, Konturek PC, Koebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur Respir J 2003; 22: 251-257.
155. Ambrosini G, Nath AK, Sierra-Honigmann MR, et al. Transcriptional activation of the human leptin gene in response to hypoxia. Involvement of hypoxia-inducible factor 1. J Biol Chem 2002; 277: 34601-34609.
156. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-1830.
157. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-355.
158. Hosogai N, Fukuhara A, Oshima K, et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 2007; 56: 901-911.
159. 2- regulated gene expression. Faseb J 2002; 16: 1151-1162.
160. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009; 33: 1195-1205.
161. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-866.
162. Sell H, Eckel J. Monocyte chemotactic protein-1 and its role in insulin resistance. Curr Opin Lipidol 2007; 18: 258-262.
163. Shoelson SE, Lee J, Yuan M. Inflammation and the IKKβ/IκB/ NF-κB axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord 2003; 27: Suppl. 3, S49-S52.
164. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB. Nat Med 2005; 11: 183-190.
165. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51.
166. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
167. Ryan S, Taylor CT, McNicholas WT. Predictors of elevated nuclear factor-κB-dependent genes in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2006; 174: 824-830.
168. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intimamedia thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 625-630.
169. Baguet JP, Hammer L, Levy P, et al. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 2005; 128: 3407-3412.
170. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 613-618.
171. Drager LF, Bortolotto LA, Figueiredo AC, et al. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176: 706-712.
172. Lorenzi-Filho G, Drager LF. Obstructive sleep apnea and atherosclerosis: a new paradigm. Am J Respir Crit Care Med 2007; 175: 1219-1221.
173. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004; 27: 1507-1511.
174. Taheri S, Austin D, Lin L, et al. Correlates of serum C-reactive protein (CRP)-no association with sleep duration or sleep disordered breathing. Sleep 2007; 30: 991-996.
175. Ryan S, Nolan GM, Hannigan E, et al. Cardiovascular risk markers in obstructive sleep apnoea syndrome and correlation with obesity. Thorax 2007; 62: 509-514.
176. Alam I, Lewis K, Stephens JW, et al. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. Obes Rev 2007; 8: 119-127.
177. Thalmann S, Meier CA. Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 2007; 75: 690-701.
178. Levy P, Pepin JL, Arnaud C, et al. Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. Eur Respir J 2008; 32: 1082-1095.
179. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97: 698-706.
180. Dematteis M, Julien C, Guillermet C, et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008; 177: 227-235.
181. Volgin DV, Kubin L. Chronic intermittent hypoxia alters hypothalamic transcription of genes involved in metabolic regulation. Auton Neurosci 2006; 126-127: 93-99.
182. Jun J, Polotsky VY. Sleep disordered breathing and metabolic effects: evidence from animal models. Sleep Med Clin 2007; 2: 263-277.
183. Savransky V, Nanayakkara A, Li J, et al. Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 2007; 175: 1290-1297.
184. Li J, Savransky V, Nanayakkara A, et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 2007; 102: 557-563.
185. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-857.
186. Li J, Bosch-Marce M, Nanayakkara A, et al. Altered metabolic responses to intermittent hypoxia in mice with partial deficiency of hypoxia-inducible factor-1α. Physiol Genomics 2006; 25: 450-457.
187. Yokoe T, Alonso LC, Romano LC, et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pancreatic betacell replication in mice. J Physiol 2008; 586: 899-911.
188. Li J, Grigoryev DN, Ye SQ, et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 2005; 99: 1643-1648.
189. Polotsky VY, Li J, Punjabi NM, et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 2003; 552: 253-264.
190. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845.
191. Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007; 293: G871-G877.
192. Savransky V, Nanayakkara A, Vivero A, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 2007; 45: 1007-1013.
193. Savransky V, Jun J, Li J, et al. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 2008; 103: 1173-1180.
194. Verhulst SL, Jacobs S, Aerts L, et al. Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents? Sleep Breath 2009; 13: 207-210.